{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:34:18Z","timestamp":1671593658117},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The use of proteasome inhibitors and immunomodulatory agents in the treatment of myeloma have resulted in significant improvements in patient outcomes over the last decade. Although these agents now form the backbone of current myeloma treatment regimens both in the frontline and in a relapsed setting, drug resistance remains an inevitable challenge that most patients will encounter during their disease course. Hence, new treatment strategies continue to be explored, and the recent regulatory approvals of the monoclonal antibodies (mAbs) daratumumab (DARA) and elotuzumab (ELO), which target the plasma cell surface proteins CD38 and signaling lymphocytic activation molecule F7 (SLAMF7), respectively, have heralded the long-awaited era of antibody-based approaches in the treatment of myeloma. Hoping to build on these advances, a number of other mAbs are in various stages of clinical development, including those targeting myeloma cell surface antigens, the bone marrow microenvironment, and immune effector T cells such as anti-programmed cell death protein 1 antibodies. In this review, the current landscape and practical use of mAb-based therapy in myeloma will be discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.512","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"512-520","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Advances and practical use of monoclonal antibodies in multiple myeloma therapy"],"prefix":"10.1182","volume":"2016","author":[{"given":"Hans C.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111704243511500_B1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111704243511500_B2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/10428194.2015.1102245","article-title":"Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: a new era begins","volume":"57","author":"Magarotto","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111704243511500_B3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111704243511500_B4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111704243511500_B5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"suppl 15","key":"2019111704243511500_B6","article-title":"MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: data from clinically relevant cohorts from a phase I\/IIa study [abstract]","volume":"34","author":"Raab","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019111704243511500_B7","article-title":"Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"34","author":"Richter","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111704243511500_B8","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood.V124.21.4736.4736","article-title":"Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib [abstract]","volume":"124","author":"Kelly","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111704243511500_B9","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1158\/1078-0432.CCR-14-3090","article-title":"A phase I dose-escalation study of antibody BI-505 in relapsed\/refractory multiple myeloma","volume":"21","author":"Hansson","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111704243511500_B10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111704243511500_B11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"Lonial","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2019111704243511500_B12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2019111704243511500_B13","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111704243511500_B14","article-title":"Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study [abstract]","volume":"34","author":"Palumbo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704243511500_B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract]","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111704243511500_B16","article-title":"A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len\/Dex) in relapsed\/refractory multiple myeloma (RRMM): interim results from two new dose cohorts [abstract]","volume":"34","author":"Vij","year":"2016","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111704243511500_B17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","article-title":"Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract]","volume":"124","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111704243511500_B18","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis [abstract]","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704243511500_B19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"126","author":"Badros","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111704243511500_B20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111704243511500_B21","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111704243511500_B22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2019111704243511500_B23","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111704243511500_B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"16","key":"2019111704243511500_B25","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704243511500_B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2019111704243511500_B27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"issue":"3","key":"2019111704243511500_B28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"2019111704243511500_B29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"suppl 1","key":"2019111704243511500_B30","first-page":"342","article-title":"An open-label, randomised, phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX [abstract]","volume":"101","author":"Dimopoulos","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111704243511500_B31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"2019111704243511500_B32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"issue":"6 pt 2","key":"2019111704243511500_B33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"6","key":"2019111704243511500_B34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2019111704243511500_B35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"2019111704243511500_B36","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111704243511500_B37","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.4049\/jimmunol.180.4.2294","article-title":"Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats","volume":"180","author":"Tawara","year":"2008","journal-title":"J Immunol"},{"issue":"13","key":"2019111704243511500_B38","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111704243511500_B39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2019111704243511500_B40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/512\/1251262\/hem088353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/512\/1251262\/hem088353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:24:49Z","timestamp":1573982689000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/512\/21092\/Advances-and-practical-use-of-monoclonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.512","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}